More Details on This News

Shilpa Medicare Limited, along with its material subsidiary Shilpa Pharma Lifesciences Ltd and wholly owned subsidiary FTF Pharma Pvt Ltd, has received an ex parte ad-interim injunction order from the Delhi High Court. The order restrains the company from manufacturing, stockpiling, exporting, offering for sale, and supplying the pharmaceutical drug product containing Ruxolitinib and/or Ruxolitinib Salts API, which allegedly infringes Patent No. IN269841.

A Local Commissioner and their team inspected the company's office premises, reviewing ledgers and stock registers. Shilpa Medicare stated that it fully cooperated with the officials and provided the requested information. The company clarified that the product in question was utilized solely for research purposes and that there is no financial impact on the company from this development. Business operations are continuing as usual and were not impacted by the inspection.

The company is currently evaluating its legal options, including filing appropriate responses or appeals, as advised by its counsel. The announcement was made pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.